Navigation Links
Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
Date:8/14/2009

community, we should have data compliant with the requirements of a multi-national study that can be submitted to the FDA as well as Swissmedic."

The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte would start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers and cosmetic applications. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the start of a Phase II
'/>"/>

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
2. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
3. Earths Oxygen May Have Arrived Earlier
4. San Diegos SeQual Technologies Loans 35 Portable Oxygen Units to Evacuees at Qualcomm Stadium
5. CQRC Statement on the NY Times Article on Medicares Home Oxygen Benefit
6. Statement from American Association for Homecare on New York Times Article about Home Oxygen Therapy
7. Link between chronic kidney disease and oxygen-deprived tissue
8. FOXO factor promotes survival of oxygen-deprived cancer cells
9. Infants with birthmarks received less oxygen in womb
10. OxySure(R) Systems, Inc. Named to 2008 Worlds Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks
11. Home Oxygen Care Leaders Say Presidents Budget Will Lead to Significant Patient Service Disruptions, Call for Thoughtful Reforms as Opposed to Repeated Cuts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013 For more than forty years, ... battle against drug and alcohol abuse around the world. ... first guide to help Italian speakers reverse growing trends ... European Monitoring Centre for Drugs and Drug Addiction show ... cannabis in the last year. As a glimpse of ...
(Date:5/20/2013)... child whose mother lived near heavy traffic while pregnant ... infection before the age of 3, a new study ... pairs of mothers and infants from eastern Massachusetts. All ... trimester of pregnancy at some point between 1999 and ... within 100 meters (about 110 yards) from a major ...
(Date:5/20/2013)... Posterior fossa subdural hematoma (PFSDH) is a serious and ... But with appropriate treatment, there,s an excellent chance of ... reports a study in the May issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , The results ...
(Date:5/20/2013)... As high schoolers prepare for final exams, teens ... -- a prescription stimulant or amphetamine -- to gain ... poll shows only one in 100 parents of teens ... a study drug., Study drugs refer to stimulant medications ... disorder (ADHD); commonly prescribed medicines in this category include ...
(Date:5/20/2013)... three out of four pregnant women experience constipation, diarrhea ... University Medical Center study has found. , But such ... quality of life, the study found. , The study ... was presented during the American Congress of Obstetricians and ... One hundred and four pregnant women were enrolled and ...
Breaking Medicine News(10 mins):Health News:First Narconon Cannabis Abuse Prevention Guide Takes Aim at Drug Abuse Statistics for Italian Youth 2Health News:Living Near Major Roadways in Pregnancy Tied to Respiratory Woes in Children 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:72 percent of pregnant women experience constipation and other bowel problems 2
... has confirmed the presence of H5N1 bird flu strain in ... of the deadly bird flu strain // in six villages ... ,Early this month five new cases of bird ... flu was first detected in Danube delta in Romania this ...
... has been passed in United Kingdom which allows prescription ... 12 and pregnant women as the risk associated with ... nicotine patches as earlier the sale of nicotine patches ... women and people with chronic diseases such as heart, ...
... The first Chinese outbreak of H5N1 bird flu infection occurred ... thursday the Chinese officials have confirmed // the seventh death ... Zhou was a 41 year old women factory worker of ... and pneumonia, who had an initial H5N1 virus test negative. ...
... from injury tissue by increasing the number of circulating ... ,The report, to be published in the April ... Physiology, says a typical course of hyperbaric oxygen treatments ... patient`s body by eight-fold. ,Stem cells, also ...
... has indicated that China might be using "substandard poultry vaccine", ... deadly outbreaks of bird flu //in that country. ... Memphis, Tennessee, however said that this problem was not confined ... blame China for substandard vaccines. I think there are substandard ...
... As a coin has two sides so does vitamin D, it ... and liver. If taken in high doses vitamin D can be ... based on intakes from 63 studies. , ,The study was ... Garland looked at the relationship between blood levels of Vitamin D ...
Cached Medicine News:
(Date:5/20/2013)... CHICAGO, Ill. , May 20, 2013 /PRNewswire/ ... the initiation of a Phase 3 clinical study ... to assess the effects of the investigational compound ... progression of kidney disease in patients with stage ... type 2 diabetes.  SONAR is a large, multinational, ...
(Date:5/19/2013)...  The non-surgical Stretta® procedure employing ... is effective in control of gastroesophageal reflux disease ... medication 10 years post-procedure, according to an independent, ... Disease Week (DDW) meeting May 18-21, 2013 in ... "The sustained improvement in GERD-HRQL scores and ...
(Date:5/17/2013)... SHANGHAI , May 17, 2013 Medical ... drug nor a biological product. In light of their ... trail evaluations are much more complicated than drug trails ... only evaluates MD safety instead of evaluating both safety ... the US FDA (which is the same as the ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3Statistical Challenges in Medical Device Trail Evaluation 2
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: